‘TIME SAVED’ AS A DEMONSTRATION OF CLINICAL MEANINGFULNESS AND ILLUSTRATED USING THE DONANEMAB TRAILBLAZER-ALZ STUDY FINDINGS
S.P. Dickson, A.M. Wessels, S.A. Dowsett, C. Mallinckrodt, J.D. Sparks, S. Chatterjee, S. Hendrix
J Prev Alz Dis 2023;3(10):595-599
In Alzheimer’s disease (AD) clinical trials, disease-modifying therapies are expected to slow the rate of disease progression. Treatment effects are evaluated using a validated clinical scale as the difference between treatment and placebo in mean change from baseline to endpoint. Understanding the clinical relevance of this metric is not necessarily intuitive. Expressing active treatment-placebo difference as a time metric (i.e., months saved with treatment) has potential to provide a metric that is more easily and consistently interpreted. Using data from the TRAILBLAZER-ALZ study, time component tests (TCTs) were employed to determine the time saved with donanemab (an amyloid lowering drug) treatment. At study endpoint (Week 76), disease progression was delayed by 5.3 months and 5.2 months as measured by the Integrated Alzheimer’s Disease Rating Scale (iADRS) and the Clinical Dementia Rating Sum of Boxes (CDR-SB), respectively.
S.P. Dickson ; A.M. Wessels ; S.A. Dowsett ; C. Mallinckrodt ; J.D. Sparks ; S. Chatterjee ; S. Hendrix (2023): ‘Time Saved’ As a Demonstration of Clinical Meaningfulness and Illustrated Using the Donanemab TRAILBLAZER-ALZ Study Findings. The Journal of Prevention of Alzheimer’s Disease (JPAD). http://dx.doi.org/10.14283/jpad.2023.50